Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS study-Reference-Cited by-同舟云学术

Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS study

Published:2018-01-03 Issue:9 Volume:59 Page:2075-2084
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Cramer Paula¹,Fraser Graeme²,Santucci-Silva Rodrigo³,Grosicki Sebastian⁴,Dilhuydy Marie-Sarah⁵,Janssens Ann⁶,Loscertales Javier⁷,Rule Simon⁸,Goy Andre⁹,Traina Shana¹⁰,Chan Eric K. H.¹⁰,Diels Joris¹¹,Sengupta Nishan¹²,Mahler Michelle¹⁰,Salman Mariya¹⁰,Howes Angela¹³,Chanan-Khan Asher¹⁴

Affiliation:

1. Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital Cologne, Cologne, Germany;

2. Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada;

3. Hemomed Oncologia e Hematologia, IEP São Lucas, São Paulo, Brazil;

4. Silesian Medical University, Katowice, Poland;

5. Hôpital Haut-Lévêque, Pessac, France;

6. Universitaire Ziekenhuizen Leuven, Leuven, Belgium;

7. Hematology Department, Hospital Universitario La Princesa, IIS-IP, Madrid, Spain;

8. Plymouth University Medical School, Plymouth, UK;

9. John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA;

10. Janssen Global Services, Raritan, NJ, USA;

11. Janssen EU HEMAR Statistics & Modelling, Beerse, Belgium;

12. Janssen Global Oncology, Raritan, NJ, USA;

13. Janssen Research & Development, High Wycombe, UK;